Ipsen: Q3 sales up 18.3%
(CercleFinance.com) - The biopharmaceutical company Ipsen has reported sales of 555.
9 million euros for the third quarter of 2018, up 18.3% as reported and up 20.2% excluding currency effects.
Specialty medical sales reached 484.1 million euros, up 24.2% at constant exchange rates, while those in family health were 71.9 million euros, up 5% at constant exchange rates and adjusted for the new contractual model of Etiasa.
Ipsen confirms its financial targets for FY 2018, with Group sales up over 19% excluding FX factors, and an operating margin of businesses of approximately 29% of sales.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
9 million euros for the third quarter of 2018, up 18.3% as reported and up 20.2% excluding currency effects.
Specialty medical sales reached 484.1 million euros, up 24.2% at constant exchange rates, while those in family health were 71.9 million euros, up 5% at constant exchange rates and adjusted for the new contractual model of Etiasa.
Ipsen confirms its financial targets for FY 2018, with Group sales up over 19% excluding FX factors, and an operating margin of businesses of approximately 29% of sales.
Copyright (c) 2018 CercleFinance.com. All rights reserved.